Skip to content
lifestyle.imone2015.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immunogenesis Inc.
ImmunoGenesis Announces Two Publications Highlighting the Potential of IMGS-203, a Novel Stimulator of Interferon Genes (STING) Agonist, to Overcome Tumor Immune Resistance and Enhance Antitumor Efficacy in Combination with a Cytotoxic Dual-specific PD-L1/PD-L2 Antibody
November 5, 2026
ImmunoGenesis to Present IND-Enabling Development Progress and Therapeutic Potential of IMGS-203, a Novel STING Agonist, at SITC 2026 Annual Meeting
November 4, 2026
ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors
September 9, 2026
ImmunoGenesis Appoints Chief Medical Officer
May 28, 2026